Role of reduced ADAMTS13 in arterial ischemic stroke: A pediatric cohort study
Role of reduced ADAMTS13 in arterial ischemic stroke: A pediatric cohort study
Objective: Previous studies in adults and mice have implicated ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as von Willebrand factor (VWF)-cleaving protease, as a protective factor for stroke. Here we investigated ADAMTS13 in 208 pediatric patients with arterial ischemic stroke (AIS) and 125 population-based control children in a frequency-matched case-control study. Methods: The proportion of patients/controls with ADAMTS13 activity levels below and above the 10th percentile was compared. Additionally, in a quintile comparison, the proportion of patients versus controls in the lowest ADAMTS13 quintile was compared to those in the 2nd to 5th quintiles. Adjustment was performed for VWF antigen (VWF:Ag), factor VIII activity (FVIII:C), blood group, and age. Results: Forty-six of 208 patients (22%) showed ADAMTS13 levels below the 10th percentile, compared with 5 of 125 controls (4%; p < 0.001). Odds ratios/95% confidence intervals were 7.30/2.73-19.50 for the lowest percentile and 2.44/1.15-5.16 in the quintile comparison after adjustment for VWF:Ag, FVIII:C, blood group, and age. Comparing the proportion of patients with ADAMTS13 activity below the 10th percentile within the different stroke subtypes (undetermined, cardioembolic, steno-occlusive arteriopathies), no statistically significant differences were found (undetermined, 16 of 89; cardioembolic, 6 of 40; steno-occlusive arteriopathies, 24 of 79; p = 0.08). ADAMTS13 levels did not significantly differ among stroke subtypes (p = 0.29). Interpretation: Our findings implicate reduced ADAMTS13 activity as a risk factor for pediatric AIS, and support the concept that ADAMTS13 has a role in the pathogenesis of pediatric AIS.
58-64
Lambers, Moritz
ec1cef61-6bdb-45cd-b10c-cb0ec61f7086
Goldenberg, Neil A.
f1e94433-989d-4db5-8d9d-df4c590a7b4a
Kenet, Gili
f3eb07f4-717a-432a-8cd6-570eed147e64
Kirkham, Fenella J.
1dfbc0d5-aebe-4439-9fb2-dac6503bcd58
Manner, Daniela
d2edbdbd-da37-4c43-8a82-5d37c03d37e8
Bernard, Timothy
7f3e982c-c7a4-425d-972e-bb74c1dc91cc
Mesters, Rolf M.
86b1b954-8c53-49ae-b21e-6f42fe0f5691
Junker, Ralf
6593e8c9-f780-4790-9f09-48b75bb1d59b
Stoll, Monika
32bba441-a39c-4bfa-928c-14012ae95aaf
Nowak-Göttl, Ulrike
ccdfa168-34d8-4aeb-9f93-bd1fa432b4ff
January 2013
Lambers, Moritz
ec1cef61-6bdb-45cd-b10c-cb0ec61f7086
Goldenberg, Neil A.
f1e94433-989d-4db5-8d9d-df4c590a7b4a
Kenet, Gili
f3eb07f4-717a-432a-8cd6-570eed147e64
Kirkham, Fenella J.
1dfbc0d5-aebe-4439-9fb2-dac6503bcd58
Manner, Daniela
d2edbdbd-da37-4c43-8a82-5d37c03d37e8
Bernard, Timothy
7f3e982c-c7a4-425d-972e-bb74c1dc91cc
Mesters, Rolf M.
86b1b954-8c53-49ae-b21e-6f42fe0f5691
Junker, Ralf
6593e8c9-f780-4790-9f09-48b75bb1d59b
Stoll, Monika
32bba441-a39c-4bfa-928c-14012ae95aaf
Nowak-Göttl, Ulrike
ccdfa168-34d8-4aeb-9f93-bd1fa432b4ff
Lambers, Moritz, Goldenberg, Neil A., Kenet, Gili, Kirkham, Fenella J., Manner, Daniela, Bernard, Timothy, Mesters, Rolf M., Junker, Ralf, Stoll, Monika and Nowak-Göttl, Ulrike
(2013)
Role of reduced ADAMTS13 in arterial ischemic stroke: A pediatric cohort study.
Annals of Neurology, 73 (1), .
(doi:10.1002/ana.23735).
Abstract
Objective: Previous studies in adults and mice have implicated ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as von Willebrand factor (VWF)-cleaving protease, as a protective factor for stroke. Here we investigated ADAMTS13 in 208 pediatric patients with arterial ischemic stroke (AIS) and 125 population-based control children in a frequency-matched case-control study. Methods: The proportion of patients/controls with ADAMTS13 activity levels below and above the 10th percentile was compared. Additionally, in a quintile comparison, the proportion of patients versus controls in the lowest ADAMTS13 quintile was compared to those in the 2nd to 5th quintiles. Adjustment was performed for VWF antigen (VWF:Ag), factor VIII activity (FVIII:C), blood group, and age. Results: Forty-six of 208 patients (22%) showed ADAMTS13 levels below the 10th percentile, compared with 5 of 125 controls (4%; p < 0.001). Odds ratios/95% confidence intervals were 7.30/2.73-19.50 for the lowest percentile and 2.44/1.15-5.16 in the quintile comparison after adjustment for VWF:Ag, FVIII:C, blood group, and age. Comparing the proportion of patients with ADAMTS13 activity below the 10th percentile within the different stroke subtypes (undetermined, cardioembolic, steno-occlusive arteriopathies), no statistically significant differences were found (undetermined, 16 of 89; cardioembolic, 6 of 40; steno-occlusive arteriopathies, 24 of 79; p = 0.08). ADAMTS13 levels did not significantly differ among stroke subtypes (p = 0.29). Interpretation: Our findings implicate reduced ADAMTS13 activity as a risk factor for pediatric AIS, and support the concept that ADAMTS13 has a role in the pathogenesis of pediatric AIS.
This record has no associated files available for download.
More information
e-pub ahead of print date: 25 August 2012
Published date: January 2013
Identifiers
Local EPrints ID: 424267
URI: http://eprints.soton.ac.uk/id/eprint/424267
ISSN: 0364-5134
PURE UUID: a640e28a-43f0-47fb-809c-17fb976c93d1
Catalogue record
Date deposited: 05 Oct 2018 11:35
Last modified: 16 Mar 2024 03:22
Export record
Altmetrics
Contributors
Author:
Moritz Lambers
Author:
Neil A. Goldenberg
Author:
Gili Kenet
Author:
Daniela Manner
Author:
Timothy Bernard
Author:
Rolf M. Mesters
Author:
Ralf Junker
Author:
Monika Stoll
Author:
Ulrike Nowak-Göttl
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics